{
  "docId": "019de074-7472-72bc-8651-e49cc0d0319c",
  "docSlug": "c2a880ad0c526527fe8aa49c40270224",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 28,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a bulleted list with custom circular icons to present clinical safety findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/15",
  "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c",
  "deckJsonHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c.json",
  "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.025,
        "w": 0.243,
        "x": 0.144,
        "y": 0.948
      },
      "kind": "disclaimer",
      "text": "SAE: Serious Adverse Event | AE: Adverse Event",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9b816c2-0a70-4339-ab89-a70329585eee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.495,
        "w": 0.805,
        "x": 0.076,
        "y": 0.235
      },
      "kind": "list",
      "text": "AB-729 is generally safe and well-tolerated after repeat dosing for up to 48 weeks; No treatment-related SAEs or discontinuations due to AEs; No treatment-related Grade 3 or 4 AEs; No treatment-related Grade 3 or 4 laboratory abnormalities; Grade 1 and Grade 2 ALT elevations have improved or stabilized with continued treatment; Injection site AEs were all Grade 1 (erythema, pain, bruising); No clinically meaningful changes in ECGs or vital signs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bdaf777-57b9-48c8-800c-0527f9624193",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.085,
        "w": 0.498,
        "x": 0.076,
        "y": 0.065
      },
      "kind": "title",
      "text": "AB-729-001 Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9c16d7d-abb3-47b4-a3ac-e8ef0a256452",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "2d76ca3b-ed5f-46a6-93ea-5486e2d94cc2",
      "evidence": "list/bullet: AB-729 is generally safe and well-tolerated after repeat dosing for up to 48 weeks; No treatment-related SAEs or discontinuations due to AEs; No treatment-related Grade 3 or 4 AEs; No treatment-related Grade",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 8,
      "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}